Linked Life Data

19041831

Source:http://linkedlifedata.com/resource/pubmed/id/19041831

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2008-12-1
pubmed:abstractText
For more than a decade, positron emission tomography (PET) has had an important role in the management of thyroid cancer patients. It may be involved in initial, sometimes inadvertent, diagnosis; in postoperative evaluation; in detection of occult metastases; in the evaluation of thyroid nodules; and in prognostication of metastatic disease. In this review we will update the advances in the application of PET scanning to optimal patient management. The majority of the published studies to date have used 18F-fluoro-deoxyglucose (FDG) as the PET isotope, and unless specifically noted, all references to PET scanning will imply that this tracer has been used.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
1532-1908
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
22
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1047-59
pubmed:meshHeading
pubmed:year
2008
pubmed:articleTitle
The value of positron emission tomography (PET) in the management of patients with thyroid cancer.
pubmed:affiliation
Endocrine Division, Department of Medicine, The Methodist Hospital, Houston, TX 77030, USA. rjrobbins@tmhs.org
pubmed:publicationType
Journal Article, Comparative Study, Review